Abstract 6188: Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy

Abstract Triple-negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer. The pillar of treatment is chemotherapy, but only half of the patients have a complete response and good survival. To resolve inter- and intra-tumoral heterogeneity and determine their clinical associations, we performed single-cell RNA-sequencing and spatial transcriptomics experiments (including Xenium, Visium HD, and Visium) on treatment-naïve samples of TNBC patients in the ARTEMIS clinical trial. We find that TNBC is classified into 4 major archetypes at patient level: luminal secretory-like, basal-like, interferon responsive, and androgen receptor-enriched. At cell level, cancer cells exhibited intratumoral heterogeneity in 13 gene expression metaprograms. The TNBC tumor microenvironment (TME) consisted of 49 distinct immune and stromal cell states, many of which were reprogrammed relative to normal breast tissues from disease-free women. We further identified 8 ecotypes of cancer cells and TME cell states that co-occurred among patients and were associated with specific archetypes and chemotherapy response groups. Using the Xenium data, we identified 10 distinct spatial niches based on the co-localization of cancer and TME cells, including the tertiary lymphoid structure (TLS) niche, the immune-‘hot’ niche enriched for interferon signaling, and the EMT-associated niche characterized by the angiogenic and ECM-remodeling macrophages together with the hypoxic, EMT-related cancer cells. In contrast to previous work on T-cells, our data showed the importance of macrophage cell states and cancer cell metaprograms for interferon signaling, HLA expression and cell cycle activity that were associated with chemotherapy response. To facilitate a clinical application, we developed a 13-gene-based model of response prediction, which was validated using public TNBC cohorts. Collectively, this study provides new insights into the natural biology of untreated TNBC tumors and their association with chemotherapy response. Citation Format: Yun Yan, Yiyun Lin, Tapsi Kumar, Shanshan Bai, Aatish Thennavan, Jianzhuo Li, Tuan Tran, Min Hu, Mitchell Rao, Anna Casasent, Elizabeth Ravenberg, Gaiane Margishvili Rauch, Alyson Clayborn, Debu Tripathy, Alastair Thompson, Bora Lim, Lei Huo, Lei Huo, Stacy Moulder, Clinton Yam, Nicholas E. Navin. Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6188.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-6188
Primary Topic
Single-cell and spatial transcriptomics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 6188: Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy

Yun Yan, Gaiane M. Rauch, Yiyun Lin, Tapsi Kumar et al.
Cancer Research
Single-cell and spatial transcriptomics
article

Abstract 6188: Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy

Yun Yan, Gaiane M. Rauch, Yiyun Lin, Tapsi Kumar, Jianzhuo Li, Clinton Yam, Alyson R. Clayborn, SL Moulder, Elizabeth E. Ravenberg, Bora Lim, Mitchell Rao, Shanshan Bai, A.M. Thompson, Debu Tripathy, Anna Casasent, Min Hu, L. Huo, Tuan M. Tran, Aatish Thennavan, Nicholas E. Navin
article en

Abstract

Abstract Triple-negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer. The pillar of treatment is chemotherapy, but only half of the patients have a complete response and good survival. To resolve inter- and intra-tumoral heterogeneity and determine their clinical associations, we performed single-cell RNA-sequencing and spatial transcriptomics experiments (including Xenium, Visium HD, and Visium) on treatment-naïve samples of TNBC patients in the ARTEMIS clinical trial. We find that TNBC is classified into 4 major archetypes at patient level: luminal secretory-like, basal-like, interferon responsive, and androgen receptor-enriched. At cell level, cancer cells exhibited intratumoral heterogeneity in 13 gene expression metaprograms. The TNBC tumor microenvironment (TME) consisted of 49 distinct immune and stromal cell states, many of which were reprogrammed relative to normal breast tissues from disease-free women. We further identified 8 ecotypes of cancer cells and TME cell states that co-occurred among patients and were associated with specific archetypes and chemotherapy response groups. Using the Xenium data, we identified 10 distinct spatial niches based on the co-localization of cancer and TME cells, including the tertiary lymphoid structure (TLS) niche, the immune-‘hot’ niche enriched for interferon signaling, and the EMT-associated niche characterized by the angiogenic and ECM-remodeling macrophages together with the hypoxic, EMT-related cancer cells. In contrast to previous work on T-cells, our data showed the importance of macrophage cell states and cancer cell metaprograms for interferon signaling, HLA expression and cell cycle activity that were associated with chemotherapy response. To facilitate a clinical application, we developed a 13-gene-based model of response prediction, which was validated using public TNBC cohorts. Collectively, this study provides new insights into the natural biology of untreated TNBC tumors and their association with chemotherapy response. Citation Format: Yun Yan, Yiyun Lin, Tapsi Kumar, Shanshan Bai, Aatish Thennavan, Jianzhuo Li, Tuan Tran, Min Hu, Mitchell Rao, Anna Casasent, Elizabeth Ravenberg, Gaiane Margishvili Rauch, Alyson Clayborn, Debu Tripathy, Alastair Thompson, Bora Lim, Lei Huo, Lei Huo, Stacy Moulder, Clinton Yam, Nicholas E. Navin. Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6188.

Cancer ResearchVol. 86(7_Supplement)
The University of Texas MD Anderson Cancer Center (US), Children's Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 30%
Single-cell and spatial transcriptomics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.